960589-15-5 Usage
Uses
Used in Organic Synthesis:
(3-cyano-5-methoxyphenyl)boronic acid is used as a reagent for the formation of carbon-carbon and carbon-oxygen bonds in various chemical reactions. Its unique structure allows it to participate in a range of organic synthesis processes, making it a valuable compound in the field of chemistry.
Used in Pharmaceutical Development:
CMBA is used as a catalyst in the development of new drugs and biologically active compounds. Its ability to form stable bonds with other molecules makes it a promising candidate for creating novel pharmaceutical agents.
Used as a Fluorescent Probe:
(3-cyano-5-methoxyphenyl)boronic acid is used as a fluorescent probe for the detection of certain biomolecules. Its fluorescent properties enable researchers to track and identify specific biological targets, which can be crucial in understanding various biological processes and disease mechanisms.
Used in Disease Therapy:
CMBA has shown potential as a therapeutic agent for certain diseases. Its ability to interact with biological molecules and its versatility in chemical reactions make it a promising candidate for the development of new treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 960589-15-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,6,0,5,8 and 9 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 960589-15:
(8*9)+(7*6)+(6*0)+(5*5)+(4*8)+(3*9)+(2*1)+(1*5)=205
205 % 10 = 5
So 960589-15-5 is a valid CAS Registry Number.
960589-15-5Relevant articles and documents
2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES
-
Paragraph 00527, (2017/05/10)
Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
